Nucleotide Market Size, Share, and Industry Analysis, By Nucleotides (dATP, dCTP, dGTP, dTTP, dNTP and Others), By Grade (Industry Grade, Lab Grade, and Others), By Technology (Polymerase Chain Reaction (PCR), DNA Sequencing, Array Technologies and Others), By Form (Liquid and Powder), By Application (Molecular Biology Research, Drug Discovery, Diagnostics, Others), By End User (Pharmaceutical and, Biotechnology Companies, Research and Academic Institutes, Diagnostics Centers, and Others), and Regional Forecast, 2026-2034

The global nucleotide market size was valued at USD 1.02 billion in 2025. The market is projected to grow from USD 1.12 billion in 2026 to USD 2.34 billion by 2034, exhibiting a CAGR of 9.70% during the forecast period.

The global nucleotide market is observing significant growth due to advances in molecular biology research and therapeutics. Nucleotides are at the forefront of various technologies. They are building blocks of nucleic acid and can be utilized in all genetically modified applications in biotechnology. The ubiquitous use of nucleotides in research and gene therapies, molecular diagnostics, biotechnology tools, and synthetic biology is expected to fuel the growth of the global nucleotide market.

Furthermore, research and development in the fields of genetic engineering, biotechnology, therapeutic gene therapies, and personalized medicine to propel the growth of the market. Moreover, various key players are investing heftily in technological advancement and expansion of production capacity in the field to complement the growth of the global nucleotide market.

• For instance, in August 2023, GenScript Biotech added 400,000 square feet of single RNA and non-viral DNA manufacturing capacity at its site in Zhenjiang, China, to support biopharma cell and gene therapy (CGT) projects. The manufacturing facility is expected to utilize nucleotides for synthesis and leading to an increase in demand. Such developments are expected to fuel the market growth. 

Nucleotide Market Driver

Technological Advancement in Synthesis and Extraction Methods to Drive Market Growth 

The technological advancement in the synthesis and extraction process of nucleotides provides new frontiers to fuel the growth of the global nucleotide market. The technological advancement ensures longer, faster, and more efficient production of nucleotides. The traditional nucleotide synthesis method was limited to 350 nucleotides in length. The synthesis method adopted for longer nucleotides could not reproduce complex and repetitive sequences. Technological advancements such as enzymatic synthesis assist in clearing those hurdles, and various key companies are focusing on commercializing this novel technique.

• For instance, in January 2025, DNA Script showcased an advancement in oligonucleotide synthesis technology that enabled the production of custom DNA sequences of up to 500 nucleotides in length. Such developments are expected to bolster the growth in the forecasted period.

Pipeline of Gene, Cell, and RNA therapies, by American Society of Gene+ Cell Therapy, 2024

In 2024, the American Society of Gene+ Cell Therapy published its second quarterly report and reported that 2,068 gene therapies (including genetically modified cell therapies such as CAR-T cell therapies) were in development, accounting for 51.0% of gene, cell, and RNA therapies. All these genetically modified therapies use nucleotides in their upstream processes.

Nucleotide Market Restraint

High Prices of Nucleotides due to Complex Manufacturing Pose a Significant Challenge for Market Growth

The manufacturing process of nucleotides is an energy-intensive and complex process. These factors result in high production costs of nucleotides, which in turn result in high prices of nucleotides. The cost of nucleotide synthesis also includes the cost of synthesizing the intermediate metabolites. Moreover, these nucleotides need to be purified for further viable use. This purification process needs specialized reagents and sensitive downstream processes that further add to its cost.

• For example, BioBasic reported a price of USD 0.18 per base pair. Similarly, a purification kit such as Pro TechEx-Oligonucleotide Purification Teaching Kit was priced as high as 98.0 per kit. Similarly, large DNA extraction equipment is required, which commands high investments.
• For example, Thermo Fisher Scientific offers automated DNA extraction systems such as the KingFisher series, with prices ranging from USD 10,000 to USD 30,000, depending on the model and features. Such factors can pose a significant challenge to market growth. Such high prices adversely affect the product adoption, hence restricting market growth. 

Nucleotide Market Opportunity

Extensive Use of Nucleotides for Novel Therapies to Offer Lucrative Market Growth Opportunity

The global nucleotide market is expected to witness various growth avenues in the field of therapeutic biotechnology, such as gene therapy, precision medicine and synthetic biology, and CRISPR technology etc. Nucleotides are building blocks of nucleic acids and are required in large quantities for application in novel therapeutic techniques. Thus, with increasing research and development of gene-related therapies, the demand for pure, industrial-grade nucleotides is expected to rise. These therapeutic applications provide a significant growth opportunity for the market.

Additionally, strategic activities such as the expansion of product offerings, collaborations, and acquisitions by key companies aim to capitalize on the growing market to offer expansion avenues.

• For instance, in July 2025, Integrated DNA Technologies (IDT) expanded its product offering in the fields of gene editing with additions to its end-to-end CRISPR portfolio. These expanded CRISPR translational research solutions were designed to help researchers accelerate more CRISPR-based therapies for patients. Such advancements are expected to heighten the demand and open new avenues for growth.

Key Insights

The report covers the following key insights:

• Technological Advancements in the Market
• Application of Nucleotides in Different Therapeutic Areas
• Pricing Analysis, Key Products, by Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

Segmentation

Analysis by Nucleotides

By Nucleotides, the market is divided into dATP, dCTP, dGTP, dTTP, dNTP, and others. 

The dNTP (Deoxynucleotide triphosphate) segment is expected to dominate the global nucleotides market. The high segmental share is accredited due to varied applications of dNTPs in research, genetic testing, molecular labelling, and PCR techniques.

• For example, during PCR, the dNTP phosphate group is used in the extension process that assists in elongation. Such a crucial role of dNTP in PCR is associated with a high segmental share.

Analysis by Grade

By grade, the market is divided into industry grade, lab grade, and others.

The lab grade is expected to hold a considerable share of the global market. The high share of the segment is attributed to increasing diagnostics, PCR, NGS, synthetic biology, and increasing research activities. These applications require nucleotides in large volumes, resulting in increased demand. Additionally, many key operating players in the market are focusing on expanding their production capacity to meet the rising demand for lab-grade nucleotides.

• For instance, in June 2024, Bionova Scientific invested USD 100.0 million to expand into plasmid DNA (pDNA) production. The company offered pDNA development services and production of research-grade and high-quality pDNA. Such production facilities use nucleotides in high volumes for the synthesis of plasmid DNA and are expected to drive the segmental growth. 

Analysis by Technology

By technology, the market is divided into polymerase chain reaction (PCR), DNA sequencing, array technologies, and others.

Polymerase chain reaction is expected to hold a substantial market share of the global nucleotide market. PCR tools extensively utilize nucleotides in every step of PCR. Nucleotides are building blocks of nucleic acids and provide a template for DNA synthesis. The wide applications of PCR in research and molecular diagnostics are expected to fuel the growth of the segment in the forecasted years. 

Additionally, underlining the varied applications of PCR and the rise in demand for nucleotides due to its application in PCR, various established players in the market shifted their focus toward research and development to support advancement in technology. This led to innovative product development.

• For instance, in April 2025, Seegene Inc., a global leader in molecular diagnostics (MDx), introduced CURECA at ESCMID Global 2025. CUREA is a fully automation system that covers the PCR workforce, from sample pre-processing to result analysis. The PCR tools use nucleotides for their elongation steps. Thus, such developments in the PCR workforce are expected to fuel the market further.

Analysis by Form

On the basis of form, the global nucleotide market is classified into powder and liquid. The powder segment is expected to make up a considerable market share in the forthcoming years. The popularity of powdered nucleotides is driven by more stability and longer shelf life, and easy storage. These factors result in the preference for the powdered form of nucleotides.

• For example, among the products showcased on Thermo Fisher Scientific Inc., many nucleotide products, such as beta-Nicotinamide Adenine Dinucleotide, were available in powdered form.

 Analysis by Application 

By application, the market is divided into molecular biology research, drug discovery, diagnostics, and others.

The molecular biology research segment is expected to account for a substantial share of the global market. The high segmental share is attributed to the ubiquitous use of nucleotides for different applications in biological research, such as mRNA synthesis, DNA replication, and other biotechnology applications. This drives the demand for nucleotides in the molecular research market.

Furthermore, various key operational entities are shifting their resources toward strategic acquisitions to expand the product offering of nucleotides to cater to the increasing demand.

• For instance, in January 2022, Maravai LifeSciences, Inc. acquired MyChem LLC.. The acquisition expanded the company's product offering of ultra-pure nucleotides to customers in the diagnostics, pharma, genomics, and research markets. The products included modified nucleotides and other inputs used for mRNA synthesis, such as strategic initiatives to propel the segmental growth in the global market.

Analysis by End User 

By end user, the market is divided into pharmaceutical and biotechnology companies, research and academic institutes, diagnostics centers, and others.

Pharmaceutical and biotechnology companies are expected to hold a substantial market share over the forecast period. The high market share of the segment is attributed to the extensive use of nucleotides for therapeutic and diagnostic applications. To support the increasing demand, various established pharmaceutical and biotechnology companies are focusing on the expansion of manufacturing capacity and directing resources toward facility launch.

• For instance, in January 2023, Agilent Technologies Inc. invested approximately USD 725.0 million to double the manufacturing capacity of therapeutic nucleotides in response to the rapid growth of the market and strong demand for high-quality active pharmaceutical ingredients (API).

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America accounted for the largest global nucleotide market share in 2024. The market growth in the region is attributed to high investment in research and development, robust healthcare infrastructure, and the presence of prominent companies in the region. 

Furthermore, high investment in technological advancement in the region is expected to assist the market growth. 

• For instance, in December 2024, GeneLab received an Illumina NovaSeq 6000 sequencing instrument from NASA. This sequencer generates 3 trillion bases of sequencing data every two days (6 Tb of data), and was used by GeneLab to maximize the data and knowledge generated from precious biological spaceflight experiments—such developments propel the market growth.

Europe is expected to hold a substantial market share in the global nucleotide market. The region's high market share is due to high funding initiatives, numerous research and development efforts, coupled with government support in the region. 

• For instance, in September 2024, Takara Bio Europe, a subsidiary of Takara Bio Inc., launched the Shasta Single-Cell System at the 2024 Human Cell Atlas General Meeting. This Next Generation Sequencing (NGS) solution enabled novel biomarker discovery in oncology research. The solution combined bioinformatics tools, allowing researchers to mine more genomic and transcriptomic information at a larger scale while reducing both time and costs. Such developments are expected to boost the market growth in the upcoming years.

Asia Pacific is expected to grow with a significant CAGR during the forecast period. The regional growth is attributed to increasing demand for personalized medicine, gene therapies, and molecular diagnostic tools utilizing nucleotides. Additionally, key operational entities are focusing on strategic collaborations to expand the market reach in emerging economies such as the Asia Pacific.

• For instance, in April 2022, DNA Script partnered with Asia Pacific distributors, including Cold Spring Biotech Corp. (China, Taiwan, and Hong Kong), Research Instruments Pte. Ltd. (Singapore), Premas Life Sciences Pvt. Ltd. (India), and Bio-Medical Science Co. Ltd. (South Korea) to meet demand for same-day enzymatic DNA synthesis. These partnerships expanded DNA Script's footprint worldwide and provided sales and support for the SYNTAX DNA printing system in labs throughout the Asia Pacific region. These collaborations are expected to bolster the growth of the market.

Key Players Covered

The global nucleotide market is consolidated with the presence of a few groups and a large number of emerging companies.

The report includes the profiles of the following key players:

• Meridian Bioscience, Inc. (U.S.)
• Thermo Fisher Scientific Inc.(U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Integrated DNA Technologies, Inc. (U.S.)
• Agilent Technologies, Inc. (U.S.)
• Maravai LifeSciences. (U.S.)

Key Industry Developments

• In November 2023, F. Hoffmann-La Roche Ltd launched the LightCycler PRO System based on the proven gold standard technology of the LightCycler Systems that came before it. The LightCycler PRO System complemented the company's molecular PCR testing portfolio.
• In October 2023, Revvity, Inc. and Element Biosciences, Inc., a developer of the AVITI System, collaborated to improve the Next Generation Sequencing research workflow. The collaboration introduced workflow solutions to save time and effort required for the genomic analysis of samples.
• In August 2022, MAIA Biotechnology, Inc., developed potential first-in-class oncology drugs and announced that it had been selected to conduct an oral presentation covering the novel THIO platform at the XIV International Round Table on Nucleosides, Nucleotides, and Nucleic Acids, which will be taking place in Stockholm.